Cannabis Health Research: Medical Evidence, Clinical Studies & Safety Data

Executive Summary

Cannabis health research has emerged as one of the most rapidly expanding fields in medical science, driven by widespread legalization and growing patient populations across the United States. As of September 2026, researchers have documented sharply different health risk profiles among medicinal cannabis users, recreational consumers, and dual-use patients who access both regulated markets. The field encompasses clinical trials examining therapeutic applications for conditions ranging from chronic pain to epilepsy, epidemiological studies tracking population-level health outcomes, and laboratory research investigating cannabinoid mechanisms of action. Federal restrictions under the Controlled Substances Act, 21 U.S.C. § 812, have historically limited research access to cannabis materials, though recent Drug Enforcement Administration policy shifts and state-level medical programs have expanded the research landscape. Current evidence suggests cannabis shows promise for specific medical conditions including chemotherapy-induced nausea, multiple sclerosis spasticity, and treatment-resistant epilepsy, while questions persist regarding long-term cardiovascular effects, mental health impacts, and optimal dosing protocols. The research pipeline now includes over 800 active clinical trials registered with ClinicalTrials.gov, representing a tenfold increase since 2016.

Why This Matters

Cannabis health research directly impacts 250 million Americans living in jurisdictions with some form of legal access, 7 million registered medical cannabis patients, and healthcare providers making evidence-based treatment recommendations. The medical cannabis market reached $18.7 billion in 2025 sales, according to industry analysts, yet physicians often lack rigorous clinical trial data to guide prescribing decisions. Patients with conditions including chronic pain, post-traumatic stress disorder, and inflammatory bowel disease increasingly request cannabis as an alternative or adjunct to conventional pharmaceuticals, creating urgent demand for safety and efficacy data. The stakes extend beyond individual patient care. Health insurers evaluate whether to cover medical cannabis based on research quality. State legislatures add or remove qualifying conditions for medical programs based on emerging evidence. Federal agencies including the Food and Drug Administration and National Institutes of Health allocate hundreds of millions in research funding based on demonstrated therapeutic potential. The September 2026 analysis identifying differential health risks among user categories underscores how research findings shape regulatory frameworks and clinical guidelines. Employers implementing workplace drug policies, law enforcement agencies enforcing impaired driving statutes, and parents making decisions about adolescent access all rely on health research to inform their positions. The research also carries significant implications for the pharmaceutical industry, as demonstrated by FDA approval of Epidiolex (cannabidiol) in 2018 for seizure disorders and ongoing clinical trials of synthetic cannabinoids for various indications.

Background and History

Modern cannabis health research traces its origins to the 1964 isolation of delta-9-tetrahydrocannabinol by Israeli scientist Raphael Mechoulam, though medicinal cannabis use dates back millennia.

Ancient and Early Modern Use (Pre-1900)

Cannabis appeared in Chinese pharmacopeias as early as 2737 BCE, recommended for conditions including gout, rheumatism, and malaria. Indian Ayurvedic texts documented cannabis preparations for pain relief and digestive disorders. Western medical interest emerged in the 1830s when Irish physician William Brooke O'Shaughnessy published observations of cannabis use in India, leading to widespread adoption in European and American medicine. By 1850, cannabis extracts entered the United States Pharmacopeia, with pharmaceutical companies including Eli Lilly and Parke-Davis marketing cannabis tinctures for pain, inflammation, and insomnia.

Prohibition Era Research Drought (1937-1996)

The Marihuana Tax Act of 1937 effectively ended legal cannabis research in the United States by imposing prohibitive taxes and registration requirements. The Controlled Substances Act of 1970 classified cannabis as Schedule I, defined as having no accepted medical use and high abuse potential. This classification created regulatory barriers requiring researchers to obtain licenses from both the Drug Enforcement Administration and the Food and Drug Administration, then source materials exclusively from the National Institute on Drug Abuse cultivation facility at the University of Mississippi. Research during this period focused predominantly on documenting harms rather than therapeutic applications. The 1982 Institute of Medicine report "Marijuana and Health" examined adverse effects but noted potential therapeutic applications warranting further study. Federal funding flowed primarily to studies investigating addiction, cognitive impairment, and gateway drug theories.

Cannabinoid Discovery and Mechanism Research (1988-2000)

The 1988 discovery of cannabinoid receptors in rat brains by Allyn Howlett and William Devane revolutionized understanding of cannabis pharmacology. Researchers identified the CB1 receptor concentrated in the central nervous system and the CB2 receptor prevalent in immune tissues. The 1992 discovery of anandamide, the first endogenous cannabinoid, revealed that mammals produce their own cannabinoid signaling molecules. This endocannabinoid system research established biological plausibility for therapeutic effects and opened new avenues for drug development. During this period, the FDA approved dronabinol (synthetic THC marketed as Marinol) in 1985 for chemotherapy-induced nausea and AIDS wasting syndrome, followed by nabilone (Cesamet) in 1985 for similar indications. These approvals demonstrated that isolated cannabinoids could meet FDA efficacy and safety standards, though whole-plant cannabis remained Schedule I.

State Medical Programs and Research Expansion (1996-2014)

California's Proposition 215 in 1996 created the first modern state medical cannabis program, establishing legal protection for patients and physicians recommending cannabis. The measure included provisions encouraging research, though federal prohibition continued to limit academic studies. By 2010, fifteen states had enacted medical cannabis laws, creating natural experiments for epidemiological research. The University of California established the Center for Medicinal Cannabis Research in 2000 with $9 million in state funding, conducting FDA-approved clinical trials examining cannabis for neuropathic pain, multiple sclerosis, and HIV-associated sensory neuropathy. Results published between 2007 and 2013 provided the first rigorous placebo-controlled evidence that smoked cannabis reduced chronic pain intensity, though effect sizes were modest. The 2009 Ogden Memo from the Department of Justice deprioritized federal prosecution of medical cannabis patients in compliance with state law, reducing (though not eliminating) legal risks for researchers. The National Institutes of Health increased cannabis research funding from $111 million in 2015 to $196 million in 2020.

CBD Research and FDA Approval (2013-2018)

Anecdotal reports of cannabidiol efficacy for pediatric epilepsy, particularly Dravet syndrome, catalyzed intensive research into non-intoxicating cannabinoids. GW Pharmaceuticals conducted three randomized controlled trials demonstrating that CBD reduced seizure frequency in treatment-resistant epilepsy by approximately 40 percent compared to placebo. The FDA approved Epidiolex in June 2018, marking the first plant-derived cannabis medication to receive federal approval. This approval created a paradox: CBD derived from cannabis remained Schedule I, while the identical molecule in FDA-approved form became Schedule V. The 2018 Farm Bill legalized hemp-derived CBD containing less than 0.3 percent THC, further complicating the regulatory landscape and spurring research into CBD applications for anxiety, inflammation, and sleep disorders.

Contemporary Research Landscape (2018-Present)

The number of active cannabis clinical trials registered with ClinicalTrials.gov increased from 78 in 2016 to over 800 by September 2026. Research expanded beyond traditional indications to examine cannabis for opioid use disorder, traumatic brain injury, autism spectrum disorder, and Alzheimer's disease. The National Institutes of Health launched the Helping to End Addiction Long-term Initiative in 2018, allocating $140 million for cannabis and pain research. The DEA approved additional cannabis cultivation licenses for research in 2021, ending the University of Mississippi monopoly and improving researcher access to chemically diverse strains. By 2026, seven federally licensed cultivators supplied research-grade cannabis, including strains with varied THC:CBD ratios and terpene profiles unavailable from the legacy single supplier. State-funded research programs emerged in Massachusetts, Pennsylvania, and New York, requiring medical cannabis operators to contribute a percentage of revenue to research initiatives. These programs generated data on real-world patient outcomes, dosing patterns, and adverse event rates outside controlled clinical trial settings.

Key Players

National Institutes of Health

The National Institutes of Health serves as the primary federal funder of cannabis health research, distributing approximately $220 million annually across institutes including the National Institute on Drug Abuse, National Cancer Institute, and National Center for Complementary and Integrative Health. The NIH established the Cannabinoid Research Initiative in 2021 to coordinate efforts across institutes and prioritize high-impact studies. NIDA maintains the Drug Supply Program providing research-grade cannabis to federally approved investigators.

Food and Drug Administration

The FDA evaluates cannabis-derived medications through the standard drug approval process requiring Phase I, II, and III clinical trials demonstrating safety and efficacy. The agency approved three cannabinoid medications as of 2026: dronabinol, nabilone, and cannabidiol. The FDA issued guidance documents in 2020 and 2023 addressing botanical drug development pathways applicable to whole-plant cannabis formulations, though no products have completed this pathway. The agency also regulates CBD marketing claims, issuing warning letters to companies making unsubstantiated therapeutic claims.

Drug Enforcement Administration

The DEA controls researcher access to cannabis through licensing requirements under 21 C.F.R. § 1301. The agency determines which entities may cultivate cannabis for research and sets production quotas. DEA policy shifts, including the 2021 expansion of licensed cultivators and proposed rescheduling to Schedule III announced in 2024, directly impact research feasibility. Schedule III classification would reduce regulatory barriers while maintaining federal control.

University of California Center for Medicinal Cannabis Research

Established by the California legislature in 2000, the center has conducted or funded over 20 clinical trials examining cannabis for chronic pain, multiple sclerosis, HIV neuropathy, and other conditions. Research published in journals including JAMA and The Journal of Pain provided early rigorous evidence of therapeutic effects. The center maintains a research registry tracking long-term outcomes in medical cannabis patients.

GW Pharmaceuticals (Jazz Pharmaceuticals)

The British pharmaceutical company developed Epidiolex and Sativex (a THC:CBD oromucosal spray approved in over 25 countries but not the United States). Jazz Pharmaceuticals acquired GW in 2021 for $7.2 billion, continuing clinical trials examining cannabinoids for autism, schizophrenia, and epilepsy subtypes. The company demonstrated that cannabis-derived medications could meet FDA standards, establishing a pathway for other developers.

Johns Hopkins University

Johns Hopkins established a dedicated Cannabis Science Laboratory in 2020, conducting research on cannabis pharmacology, drug interactions, and therapeutic applications. Researchers published influential studies on cannabis use disorder treatment, drug-drug interactions with common medications, and cognitive effects of various cannabinoid ratios. The university offers a Cannabis Science and Medicine master's degree program training the next generation of researchers.

American Medical Association

The AMA shifted from opposition to cautious support for research expansion, adopting policy in 2019 urging rescheduling to facilitate investigation. The organization publishes cannabis research in JAMA and affiliated journals, providing peer review and dissemination for major studies. AMA policy statements guide physician education on cannabis therapeutics and risks.

Legal and Regulatory Framework

Cannabis health research operates within a complex framework spanning federal controlled substances law, FDA drug development regulations, state medical cannabis statutes, and institutional review board oversight. The Controlled Substances Act, 21 U.S.C. § 812, classifies cannabis as Schedule I, requiring researchers to obtain a DEA registration under 21 C.F.R. § 1301.18 and a separate research protocol approved by the FDA under 21 C.F.R. § 312.23. This dual-agency approval process can require 12-18 months before research begins. Schedule I classification also limits funding sources, as many private foundations avoid supporting research on substances with no accepted medical use under federal law. State medical cannabis laws create legal protection for research within state borders but do not override federal requirements. California Health and Safety Code § 11362.5 and similar statutes in 38 states establish medical cannabis programs with varying research provisions. Some states including Massachusetts and Pennsylvania mandate that licensed operators fund research as a condition of licensure, generating dedicated funding streams independent of federal sources. The FDA botanical drug guidance, published in final form in December 2023, established a pathway for whole-plant cannabis medications distinct from isolated cannabinoids. This framework requires standardized cultivation, extraction, and formulation processes ensuring batch-to-batch consistency, along with traditional safety and efficacy trials. No whole-plant product has completed this pathway as of September 2026, though several are in Phase II trials. Institutional review boards at research universities apply 45 C.F.R. § 46 human subjects protections to cannabis studies, requiring informed consent, risk-benefit analysis, and data safety monitoring. IRBs evaluate whether research benefits justify risks including potential federal prosecution, though the 2014 Rohrabacher-Farr Amendment (renewed annually through 2026) prohibits the Department of Justice from interfering with state-legal medical cannabis activities. The 2018 Farm Bill, 7 U.S.C. § 1639o, legalized hemp containing less than 0.3 percent THC, removing CBD derived from hemp from Schedule I. This created a separate regulatory category for hemp-derived cannabinoid research not requiring DEA registration, substantially expanding CBD research while maintaining restrictions on THC-containing cannabis.

Current State of Evidence

Rigorous clinical trial evidence supports cannabis efficacy for a narrow range of conditions, while observational data suggests potential benefits for others requiring confirmation through controlled studies.

Strong Evidence: FDA-Approved Indications

Randomized controlled trials demonstrated that cannabidiol reduces seizure frequency in Dravet syndrome and Lennox-Gastaut syndrome by approximately 40 percent compared to placebo, leading to FDA approval of Epidiolex. Three Phase III trials published in The New England Journal of Medicine between 2017 and 2018 established efficacy with common side effects including somnolence, decreased appetite, and diarrhea. Synthetic THC (dronabinol) showed efficacy for chemotherapy-induced nausea and AIDS-related anorexia in trials conducted in the 1980s and 1990s.

Moderate Evidence: Chronic Pain

A 2017 National Academies of Sciences, Engineering, and Medicine comprehensive review concluded that substantial evidence supports cannabis or cannabinoids for chronic pain in adults. Multiple randomized trials demonstrated modest pain reduction, typically 1-2 points on a 10-point scale. A 2022 meta-analysis in Annals of Internal Medicine examining 32 trials found that cannabis reduced pain intensity with a standardized mean difference of -0.42, considered a small to moderate effect. Evidence quality varies by pain type, with stronger support for neuropathic pain than inflammatory or cancer pain.

Moderate Evidence: Multiple Sclerosis Spasticity

Clinical trials of nabiximols (Sativex) and other cannabinoid formulations demonstrated modest improvements in patient-reported spasticity in multiple sclerosis. A 2020 Cochrane review analyzing 17 trials with 3,161 participants found that cannabinoids increased the likelihood of improvement by 30 percent compared to placebo, though objective measures showed smaller effects than subjective reports.

Limited Evidence: PTSD and Anxiety

Observational studies and small pilot trials suggest potential benefits for post-traumatic stress disorder, but large-scale randomized controlled trials remain incomplete as of September 2026. A 2021 study in The Journal of Affective Disorders found that smoked cannabis reduced PTSD symptom severity by 50 percent in a naturalistic setting, but the uncontrolled design limits conclusions. The FDA approved a Phase III trial of MDMA-assisted therapy for PTSD in 2023, but comparable cannabis trials remain in Phase II.

Emerging Research: Opioid Substitution

Ecological studies found that states with medical cannabis laws experienced 25 percent lower opioid overdose mortality rates compared to prohibition states, according to research published in JAMA Internal Medicine in 2014. Subsequent studies produced mixed results, with some finding associations disappeared after 2010. Clinical trials examining cannabis as an opioid substitute or adjunct therapy launched in 2019, with preliminary results suggesting that cannabis may allow opioid dose reduction in chronic pain patients. A 2025 study in The Lancet found that medical cannabis patients reduced opioid use by 40 percent over six months, though the observational design cannot establish causation.

Safety Concerns: Cardiovascular and Mental Health

Research increasingly documents cardiovascular risks associated with cannabis use. A 2024 American Heart Association statement noted that cannabis use increases heart attack risk in the hour following consumption, with particular concern for older adults and those with existing cardiovascular disease. A 2025 study in the Journal of the American College of Cardiology found that daily cannabis use doubled the risk of cardiovascular events over five years compared to non-use. Mental health research reveals complex relationships between cannabis and psychiatric outcomes. Multiple longitudinal studies demonstrate that adolescent cannabis use increases schizophrenia risk, particularly in individuals with genetic vulnerability. A 2023 meta-analysis in Psychological Medicine found that cannabis use before age 18 increased psychosis risk by 40 percent. Evidence regarding depression and anxiety remains mixed, with some studies suggesting therapeutic effects and others documenting increased risk with heavy use.

Differential Health Risks by User Category

The September 2026 analysis published in Medical Xpress identified sharply different health risk profiles among medicinal-only users, recreational-only consumers, and dual-use patients accessing both markets. Researchers examining data from 47,000 cannabis users found that medicinal-only patients reported higher rates of chronic health conditions including chronic pain, arthritis, and inflammatory bowel disease, as expected given medical program qualifying conditions. However, this group demonstrated lower rates of cannabis use disorder symptoms and respiratory problems compared to recreational users, potentially reflecting different consumption patterns and product choices. Recreational-only users showed higher rates of acute adverse events including anxiety, paranoia, and impaired driving incidents. This group reported more frequent use of high-potency products exceeding 20 percent THC and greater likelihood of combining cannabis with alcohol or other substances. Respiratory symptoms including chronic bronchitis appeared more common among recreational users, potentially related to higher rates of smoking versus other consumption methods. Dual-use patients accessing both medical and recreational markets demonstrated the highest overall consumption levels and greatest risk for cannabis use disorder, defined by DSM-5 criteria including tolerance, withdrawal, and unsuccessful attempts to reduce use. This group reported using cannabis more than 20 days per month on average, compared to 12 days for medicinal-only and 8 days for recreational-only users. Dual users also showed elevated rates of mental health conditions including depression and anxiety, though causation remains unclear. The analysis suggested that user category serves as a proxy for underlying health status, consumption patterns, and product selection rather than representing distinct risk profiles based solely on legal access pathway. Researchers emphasized the need for longitudinal studies tracking health outcomes as individuals transition between user categories and as product markets evolve.

Market and Business Implications

Cannabis health research directly impacts the $30 billion U.S. cannabis market by influencing product development, medical program enrollment, and pharmaceutical industry investment. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries allocate increasing resources to research partnerships and clinical trials, seeking to differentiate products through evidence-based therapeutic claims. Curaleaf invested $15 million in a partnership with the University of Maryland to study cannabis for opioid use disorder, while Trulieve funded $10 million in research at the University of Florida examining cannabis for PTSD in veterans. The pharmaceutical industry views cannabis research through a competitive lens, as evidence of therapeutic efficacy could shift patient demand from conventional medications to cannabis alternatives. A 2024 analysis in Health Affairs estimated that medical cannabis substitution reduced pharmaceutical sales by $1.2 billion annually, with particular impact on opioid analgesics, benzodiazepines, and sleep medications. This dynamic incentivizes pharmaceutical companies to either develop cannabis-derived medications or fund research documenting risks that might limit cannabis adoption. Insurance coverage decisions hinge on research quality and FDA approval status. Most health insurers do not cover medical cannabis due to lack of FDA approval and limited high-quality efficacy data, requiring patients to pay out-of-pocket costs averaging $300-500 monthly. Epidiolex coverage by Medicare and private insurers following FDA approval demonstrated how research leading to federal approval transforms market access and reimbursement. Investment in cannabis biotechnology and pharmaceutical development reached $2.3 billion in 2025, according to industry analysts, with venture capital flowing to companies conducting clinical trials of novel cannabinoid formulations, synthetic cannabinoids, and targeted delivery systems. Positive Phase II or III trial results can increase company valuations by 50-200 percent, creating strong financial incentives for rigorous research. Research documenting health risks influences product liability exposure and insurance costs for cannabis operators. Findings regarding cardiovascular risks, impaired driving, and mental health effects inform warning label requirements, age restrictions, and potency limits adopted by state regulators. Operators in states with stricter regulations based on health research face higher compliance costs but potentially reduced liability risk.

What Experts Say

Medical and scientific experts emphasize that cannabis shows promise for specific conditions while cautioning that evidence quality lags behind public perception of therapeutic benefits. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has stated that cannabis research demonstrates clear therapeutic potential for certain conditions including chronic pain and epilepsy, but that most claims lack rigorous scientific support. According to testimony before Congress in 2023, Volkow emphasized the need for large-scale, long-term studies tracking both benefits and risks as cannabis use becomes more prevalent. The American Medical Association maintains that current evidence supports cannabis for a limited range of conditions, primarily chronic pain, chemotherapy-induced nausea, and specific epilepsy syndromes. AMA policy adopted in 2019 calls for rescheduling cannabis to facilitate research while cautioning physicians that evidence remains insufficient for most conditions for which patients seek cannabis treatment. Dr. Igor Grant, director of the University of California Center for Medicinal Cannabis Research, has described cannabis as a "moderately effective" treatment for chronic pain based on clinical trial data, with effects comparable to other pain medications but not a panacea. Grant's research team found that approximately 30 percent of chronic pain patients experience meaningful relief from cannabis, while others show minimal benefit. The National Academies of Sciences, Engineering, and Medicine published a comprehensive evidence review in 2017 concluding that substantial evidence supports cannabis for chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity, while evidence for most other conditions remains limited or insufficient. The report identified major research gaps including optimal dosing, long-term safety, and comparative effectiveness versus existing treatments. Dr. Yasmin Hurd, director of the Addiction Institute at Mount Sinai, has emphasized through published research and public statements that CBD shows promise for reducing drug craving in opioid use disorder, but that THC-dominant products may worsen addiction vulnerability in some individuals. Hurd's research suggests that cannabinoid effects vary substantially based on THC:CBD ratios and individual genetic factors. The American Academy of Pediatrics maintains opposition to cannabis use in children and adolescents except for FDA-approved indications, citing evidence of cognitive effects and mental health risks. AAP policy updated in 2023 supports research access while emphasizing that developing brains face greater vulnerability to cannabis effects than adult brains.

What's Next

The cannabis health research landscape will evolve substantially over the next 24-36 months based on federal rescheduling decisions, completion of major clinical trials, and expansion of state research programs. The Drug Enforcement Administration proposed rescheduling cannabis to Schedule III in May 2024, with a final rule expected by mid-2027 following public comment and administrative law judge review. Schedule III classification would reduce regulatory barriers for researchers, eliminate the requirement for separate DEA and FDA approvals, and potentially increase National Institutes of Health funding. However, rescheduling would not legalize cannabis or eliminate all research restrictions. Multiple Phase III clinical trials examining cannabis for PTSD, autism spectrum disorder, and chronic pain will report results between late 2026 and 2028. The Multidisciplinary Association for Psychedelic Studies is conducting a 200-participant trial of whole-plant cannabis for PTSD in veterans, with results expected in March 2027. Positive results could lead to FDA approval of the first whole-plant cannabis medication, while negative results might dampen enthusiasm for cannabis as a PTSD treatment. The National Institutes of Health plans to award $75 million in new cannabis research grants in fiscal year 2027, prioritizing studies examining long-term health outcomes, optimal dosing protocols, and mechanisms of action. The agency specifically seeks applications addressing cardiovascular effects, mental health impacts in vulnerable populations, and cannabis use disorder treatment. State legislatures in Ohio, Florida, and Texas are considering bills that would establish dedicated cannabis research programs funded by medical or recreational market taxes. These state-level initiatives could generate $50-100 million in additional research funding independent of federal sources, accelerating evidence generation in areas where federal funding remains limited. The pharmaceutical industry pipeline includes at least 15 cannabinoid medications in Phase II or III trials as of September 2026, targeting indications including Tourette syndrome, inflammatory bowel disease, and traumatic brain injury. FDA approval of additional cannabinoid medications beyond Epidiolex would validate the therapeutic potential while potentially shifting market share from state-regulated cannabis to prescription medications. Longitudinal cohort studies tracking health outcomes in medical cannabis patients over 5-10 years will begin reporting results in 2027-2029, providing data on long-term safety and effectiveness currently lacking. The University of California registry includes 12,000 patients enrolled since 2020, while similar registries in Massachusetts and Pennsylvania track thousands more. International research collaboration will expand as countries including Israel, Canada, and Germany invest in cannabis science. Israel's government allocated $8 million for cannabis research in 2025, building on the country's decades of cannabinoid research leadership. Cross-national studies will provide larger sample sizes and diverse populations improving generalizability of findings.

Further Reading

• National Academies of Sciences, Engineering, and Medicine. "The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research" (2017) - https://nap.nationalacademies.org/catalog/24625
• U.S. Food and Drug Administration. "Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research" - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cannabis-and-cannabis-derived-compounds-quality-considerations-clinical-research
• National Institute on Drug Abuse. "Marijuana Research Report" - https://nida.nih.gov/publications/research-reports/marijuana
• Controlled Substances Act, 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13-subchapI-partB-sec812.htm
• ClinicalTrials.gov cannabis research registry - https://clinicaltrials.gov/search?term=cannabis
• University of California Center for Medicinal Cannabis Research - https://cmcr.ucsd.edu
• American Medical Association cannabis policy - https://www.ama-assn.org/delivering-care/public-health/cannabis-policy
• Volkow ND, et al. "Adverse Health Effects of Marijuana Use." New England Journal of Medicine 370:2219-2227 (2014) - https://www.nejm.org/doi/full/10.1056/NEJMra1402309
• Whiting PF, et al. "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis." JAMA 313:2456-2473 (2015) - https://jamanetwork.com/journals/jama/fullarticle/2338251
• DEA Diversion Control Division researcher registration - https://www.deadiversion.usdoj.gov/drugreg/index.html